The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to EOS (maximum duration of 52 weeks).
Mean Change From Baseline to Week 4 in Systolic and Diastolic Blood Pressure (BP)
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Heart Rate (HR)
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Red Blood Cell (RBC) Count
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Haemoglobin and Mean Corpuscular Haemoglobin Concentration (MCHC)
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Haematocrit
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Mean Corpuscular Haemoglobin (MCH)
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Mean Corpuscular Volume (MCV)
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in White Blood Cell (WBC) Count, Neutrophils, Lymphocytes and Platelets
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Alkaline Phosphatase (ALP), Gamma Glutamyl Transferase (GGT), Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT)
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Total Bilirubin and Creatinine
Timeframe: Baseline and Week 4 of each cycle
Mean Change From Baseline to Week 4 in Blood Urea Nitrogen (BUN) and Fasting Blood Glucose
Timeframe: Baseline and Week 4 of each cycle
Presence of Botulinum Toxin Type A (BTX-A) Neutralising Putative Antibodies (NAbs) Following Injection of Dysport®
Timeframe: At Week 4
Mean Change From Baseline to Week 4 in 12-Lead Electrocardiogram (ECG)
Timeframe: Baseline and Week 4 of each cycle